Clinical Trials Logo
  1. Home
  2. Juvenile Rheumatoid Arthritis
  3. NCT00095173

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis Clinical Trial

Official title:
A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)

Clinical Trial Summary

The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00095173
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Completed
Phase Phase 3
Start date February 2004
Completion date November 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT00004420 - Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis N/A
Completed NCT00090571 - Juvenile Rheumatoid Arthritis Research Registry
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT00010335 - Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Phase 1
Completed NCT00690573 - Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis Phase 3
Completed NCT00443430 - Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis Phase 4
Completed NCT03780959 - Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA) Phase 2/Phase 3
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT00570934 - Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA Phase 3
Recruiting NCT05715463 - Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity N/A
Completed NCT00289094 - Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA N/A
Terminated NCT00078806 - Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis Phase 3
Completed NCT00078793 - Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis N/A
Completed NCT00000429 - Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis Phase 2
Completed NCT01044823 - Use of Thermal and 3D Imaging to Quantify Arthritis N/A
Terminated NCT00029042 - Infliximab to Treat Children With Juvenile Rheumatoid Arthritis Phase 2
Withdrawn NCT00286689 - Effects of Growth Hormone in Chronically Ill Children N/A
Completed NCT00001862 - TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis Phase 2
Not yet recruiting NCT05114343 - Effectiveness and Feasibility of a Home-based Exercise Program for Adolescents With Juvenile Idiopathic Arthritis N/A
Terminated NCT03781375 - Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis Phase 3